UK Markets closed
NIKKEI 225
27,466.61 +520.94 (+1.93%) HANG SENG
19,591.43 +332.67 (+1.73%) CRUDE OIL
70.41 +0.74 (+1.06%) GOLD FUTURES
1,951.80 +10.70 (+0.55%) DOW
32,470.03 -90.57 (-0.28%) BTC-GBP
22,252.21 -669.15 (-2.92%)
Inhibikase Therapeutics, Inc. (IKT)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 01:37PM EDT
| Previous close | 0.6020 |
| Open | 0.6500 |
| Bid | 0.6020 x 1000 |
| Ask | 0.6098 x 800 |
| Day's range | 0.5958 - 0.6500 |
| 52-week range | 0.4400 - 1.5200 |
| Volume | |
| Avg. volume | 392,225 |
| Market cap | 15.189M |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7840 |
| Earnings date | 15 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Business Wire
Vetoquinol: Q1 2022 Sales: €135M
LURE, France, April 13, 2022--Regulatory News: Vetoquinol (Paris:VETO):
- Simply Wall St.
Is Inhibikase Therapeutics (NASDAQ:IKT) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
© 2023 Yahoo. All rights reserved.
